• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低分子量肝素与重组组织型纤溶酶原激活剂联合治疗可使犬冠状动脉血栓形成持续再灌注。

Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.

作者信息

Nicolini F A, Nichols W W, Saldeen T G, Khan S, Mehta J L

机构信息

Department of Medicine, University of Florida, College of Medicine, Gainesville 32610-0277.

出版信息

Am Heart J. 1992 Aug;124(2):280-8. doi: 10.1016/0002-8703(92)90588-m.

DOI:10.1016/0002-8703(92)90588-m
PMID:1322029
Abstract

Rethrombosis of the infarct-related artery after pharmacologic thrombolysis is a major limitation of the thrombolytic therapy. Platelet and fibrin deposition in the coronary artery after recombinant tissue-type plasminogen activator (rTPA) may play a leading role in reformation of thrombus. Therefore we examined the effect of low molecular weight heparin (LMWH) as adjunctive treatment with rTPA in a dog model of electrically induced intracoronary thrombus. Fourteen dogs, in which a stable coronary thrombus was induced with delivery of 100 microA of anodal direct current, were randomly given an intravenous bolus of LMWH, 75 IU/kg (n = 6), or saline (n = 8), followed by intravenous rTPA, 1 mg/kg over 20 minutes. LMWH (75 IU/kg) or saline was continuously infused over 90 minutes after rTPA-induced thrombolysis. Reperfusion occurred at 29 +/- 7 minutes in six of eight dogs receiving rTPA plus saline (reperfusion rate 75%), while reperfusion occurred at 18 +/- 3 minutes in all six dogs receiving rTPA plus LMWH (both p = NS versus rTPA plus saline group). Coronary reocclusion occurred in 83% of dogs given rTPA plus saline, but only in one dog (17%) given rTPA plus LMWH (p less than 0.05). Magnitude of reflow at 60 minutes of reperfusion was higher in the rTPA plus LMWH group than in the rTPA plus saline group (51 +/- 14 ml/min versus 10 +/- 9 ml/min; p less than 0.05). As expected, partial thromboplastin time was greater in rTPA plus LMWH than in rTPA plus saline-treated animals.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

药物溶栓后梗死相关动脉再血栓形成是溶栓治疗的主要局限。重组组织型纤溶酶原激活剂(rTPA)治疗后冠状动脉内血小板和纤维蛋白沉积可能在血栓再形成中起主要作用。因此,我们在电诱导冠状动脉血栓形成的犬模型中研究了低分子量肝素(LMWH)作为rTPA辅助治疗的效果。14只犬通过输送100微安阳极直流电诱导形成稳定冠状动脉血栓,随机静脉推注LMWH,75 IU/kg(n = 6)或生理盐水(n = 8),随后静脉给予rTPA,20分钟内给予1 mg/kg。rTPA诱导溶栓后,LMWH(75 IU/kg)或生理盐水持续输注90分钟。接受rTPA加生理盐水的8只犬中有6只在29±7分钟实现再灌注(再灌注率75%),而接受rTPA加LMWH的6只犬均在18±3分钟实现再灌注(与rTPA加生理盐水组相比,两者p =无显著性差异)。接受rTPA加生理盐水的犬中有83%发生冠状动脉再闭塞,但接受rTPA加LMWH的犬中只有1只(17%)发生再闭塞(p<0.05)。再灌注60分钟时,rTPA加LMWH组的再灌注流量幅度高于rTPA加生理盐水组(51±14 ml/min对10±9 ml/min;p<0.05)。正如预期,rTPA加LMWH组的部分凝血活酶时间比rTPA加生理盐水治疗的动物更长。(摘要截短至250字)

相似文献

1
Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.低分子量肝素与重组组织型纤溶酶原激活剂联合治疗可使犬冠状动脉血栓形成持续再灌注。
Am Heart J. 1992 Aug;124(2):280-8. doi: 10.1016/0002-8703(92)90588-m.
2
Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.低剂量血小板纤维蛋白原受体拮抗剂与直接凝血酶抑制剂联合使用可显著改善溶栓效果。
Circulation. 1994 Apr;89(4):1802-9. doi: 10.1161/01.cir.89.4.1802.
3
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.在狭窄犬冠状动脉中使用rtPA溶栓期间,依诺肝素、希美加群和肝素作为辅助抗血栓治疗的比较。
Thromb Haemost. 1997 Oct;78(4):1278-85.
4
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.硝酸甘油联合治疗未能提高组织型纤溶酶原激活剂对冠状动脉血栓形成疗效的病理基础。
Cardiovasc Res. 1991 Apr;25(4):283-9. doi: 10.1093/cvr/25.4.283.
5
Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.在犬类中,重组组织型纤溶酶原诱导溶栓后,前列环素类似物伊洛前列素未能维持冠状动脉血流。
Am Heart J. 1993 Aug;126(2):285-92. doi: 10.1016/0002-8703(93)91041-c.
6
Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.氧自由基清除剂在犬冠状动脉溶栓模型中作为组织型纤溶酶原激活剂辅助治疗的研究
Cardiovasc Res. 1993 Jun;27(6):925-34. doi: 10.1093/cvr/27.6.925.
7
Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
J Am Coll Cardiol. 1993 Sep;22(3):914-20. doi: 10.1016/0735-1097(93)90211-i.
8
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.抑肽酶,一种多肽血小板糖蛋白IIb/IIIa受体拮抗剂,在犬实验制剂中可增强并维持重组组织型纤溶酶原激活剂的冠状动脉溶栓作用。
Circulation. 1991 Mar;83(3):1038-47. doi: 10.1161/01.cir.83.3.1038.
9
Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.实验性颈静脉和冠状动脉血栓形成中的溶栓与再闭塞。1型纤溶酶原激活物抑制剂中和性单克隆抗体的作用。
Circulation. 1995 Feb 15;91(4):1175-81. doi: 10.1161/01.cir.91.4.1175.
10
Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
Circulation. 1994 Jul;90(1):427-32. doi: 10.1161/01.cir.90.1.427.

引用本文的文献

1
2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.2022 年兽医重症监护领域抗栓和溶栓药物合理应用共识更新(CURATIVE)第六域:定义溶栓药物的合理应用。
J Vet Emerg Crit Care (San Antonio). 2022 Jul;32(4):446-470. doi: 10.1111/vec.13227.
2
Case Report: Successful Reperfusion of Pulmonary Thromboembolism Using tPA in a Cat.病例报告:在一只猫身上使用组织型纤溶酶原激活剂成功实现肺血栓栓塞再灌注
Front Vet Sci. 2022 Apr 20;9:851106. doi: 10.3389/fvets.2022.851106. eCollection 2022.
3
Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.
辅助药物治疗:聚焦于低分子量肝素的研发。
J Thromb Thrombolysis. 1997;4(2):197-205. doi: 10.1023/a:1008870228789.